/
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology.
The business is unprofitable at the operating level (-18933.65% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 90.6% YoY. Margins deteriorated 17683.3pp alongside, both lines moving the wrong way.
ROIC dropped from -17.23% to -24.51%, capital efficiency is deteriorating. Negative free cash flow of -$346M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$4M
▼ -90.6% YoY
Net Income (TTM)
-$569M
▼ -58.8% YoY
Op. Margin
-15754.20%
▼ -17683.3pp YoY
ROIC
-23.25%
▼ -7.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$401M
▼ -139.1% YoY
Op. Cash Flow (TTM)
-$400M
▼ -141.7% YoY
Net Debt
-$1.65B
Net Cash Position
Cash & Equiv.
$2.44B
5Y CAGR: +37.3%
Continue Research